Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
KLRS compared with RANI: revenue, margins and what each company keeps, and the suppliers and customers both name
KLRS
Kalaris Therapeutics, Inc.
Change
Mkt cap
Revenue
Revenue
RANI
Rani Therapeutics Holdings, Inc.
Change
Mkt cap
Revenue
Revenue
vs
Compare
KLRS
Kalaris Therapeutics, Inc.
vs
RANI
Rani Therapeutics Holdings, Inc.
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
Supply-chain overlap
Revenue flow
KLRS: latest quarter not drawable. RANI: latest quarter is a loss; flow not drawable.
Method
›
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only KLRS
0
None
Shared
0
No disclosed counterparties: KLRS.
Only RANI
6
—
Celltrion
unlisted
supplier
—
Chugai Pharmaceutical
unlisted
supplier
—
ProGen
unlisted
supplier
—
ICL
unlisted
supplier
2 more · RANI chain
›
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
KLRS, solid
RANI, dashed
KLRS
Kalaris Therapeutics, Inc.
Change
2.00
▼
−6.10%
· post 2.04
Mkt cap
$48.3M
Revenue
—
RANI
Rani Therapeutics Holdings, Inc.
Change
0.60
▼
−1.49%
· post 0.60
Closed
Oct 30 '26
Mkt cap
$82.2M
Revenue
$2M
Q2 FY26
vs
Compare
Closed
Oct 30 '26
KLRS
Kalaris Therapeutics, Inc.
vs
RANI
Rani Therapeutics Holdings, Inc.
2.00
▼
−6.10%
post 2.04
Price
0.60
▼
−1.49%
post 0.60
$48.3M
Mkt cap
$82.2M
—
Revenue
$2M
Q2 FY26
Change
Change
KLRS
2.00
▼
−6.10%
vs
RANI
0.60
▼
−1.49%
Closed
Oct 30 '26